Try a new search

Format these results:

Searched for:

school:SOM

Department/Unit:Neurology

Total Results:

22908


The Bridging the Gaps Program: Three Decades of Collaborative Service-Oriented Learning in the Health Professions

Kakara, Mihir; Martinak, Ellen; McCormick, Bridget; Morales, Knashawn H; Bogner, Hillary R; Jacobs, Dina; Tuton, Lucy Wolf
Health professions educators are continuing to develop training programs for future health care professionals to understand social determinants of health and address practical needs of their training institutions via service-oriented learning. Although individual U.S. programs have piloted different models, evaluations of programs that have demonstrated longitudinal growth and sustainability in the community are lacking, which is important because these programs can have long-term impacts not only on students but also on the communities they serve. In this article, the authors describe the long-term impacts of the Bridging the Gaps (BTG) program. First established in 1991 as an academic health institution and community organization collaborative, by 2019, the BTG program encompassed 9 academic health institution-based programs, partnering with 96 community organizations and employing 187 health professions students across 15 disciplines. By 2019, the program had 5,648 alumni. Of 3,104 alumni, 2,848 (91.8%) felt that the program broadened their understanding of health issues encountered by vulnerable and/or economically disadvantaged populations, and 2,767 of 3,101 (89.2%) felt that the program increased their interest in working with these populations. A total of 142 of 156 (91.0%) reported an effect on their clinical practice, 169 of 180 (93.9%) reported an effect on their professional role, and 64 of 109 (58.7%) reported an effect on their research careers. Of the community partners, 1,401 of 1,441 (97.2%) felt that the partnership between their organization and the BTG program was beneficial, 955 of 1,423 (67.1%) felt that BTG students brought resources to their organization that had previously been unavailable, and 1,095 of 1,421 (77.1%) felt that the linkages between their agency and other organizations were strengthened. The BTG program demonstrates growth and sustainability in its ongoing efforts to integrate training on social determinants of health via service-oriented learning into health professions education.
PMID: 38113408
ISSN: 1938-808x
CID: 5773312

Association of large core middle cerebral artery stroke and hemorrhagic transformation with hospitalization outcomes

Pohlmann, Jack E; Kim, Ivy So Yeon; Brush, Benjamin; Sambhu, Krishna M; Conti, Lucas; Saglam, Hanife; Milos, Katie; Yu, Lillian; Cronin, Michael F M; Balogun, Oluwafemi; Chatzidakis, Stefanos; Zhang, Yihan; Trinquart, Ludovic; Huang, Qiuxi; Smirnakis, Stelios M; Benjamin, Emelia J; Dupuis, Josée; Greer, David M; Ong, Charlene J
Historically, investigators have not differentiated between patients with and without hemorrhagic transformation (HT) in large core ischemic stroke at risk for life-threatening mass effect (LTME) from cerebral edema. Our objective was to determine whether LTME occurs faster in those with HT compared to those without. We conducted a two-center retrospective study of patients with ≥ 1/2 MCA territory infarct between 2006 and 2021. We tested the association of time-to-LTME and HT subtype (parenchymal, petechial) using Cox regression, controlling for age, mean arterial pressure, glucose, tissue plasminogen activator, mechanical thrombectomy, National Institute of Health Stroke Scale, antiplatelets, anticoagulation, temperature, and stroke side. Secondary and exploratory outcomes included mass effect-related death, all-cause death, disposition, and decompressive hemicraniectomy. Of 840 patients, 358 (42.6%) had no HT, 403 (48.0%) patients had petechial HT, and 79 (9.4%) patients had parenchymal HT. LTME occurred in 317 (37.7%) and 100 (11.9%) had mass effect-related deaths. Parenchymal (HR 8.24, 95% CI 5.46-12.42, p < 0.01) and petechial HT (HR 2.47, 95% CI 1.92-3.17, p < 0.01) were significantly associated with time-to-LTME and mass effect-related death. Understanding different risk factors and sequelae of mass effect with and without HT is critical for informed clinical decisions.
PMCID:11063151
PMID: 38693282
ISSN: 2045-2322
CID: 5655952

Distinguishing Between Myelin Oligodendrocyte Glycoprotein Disease Optic Neuritis and Nonarteritic Anterior Ischemic Optic Neuropathy [Editorial]

Park, George T; Galetta, Steven
PMID: 38547446
ISSN: 2332-7812
CID: 5645182

The value of Clinical signs in the diagnosis of Degenerative Cervical Myelopathy - A Systematic review and Meta-analysis

Jiang, Zhilin; Davies, Benjamin; Zipser, Carl; Margetis, Konstantinos; Martin, Allan; Matsoukas, Stavros; Zipser-Mohammadzada, Freschta; Kheram, Najmeh; Boraschi, Andrea; Zakin, Elina; Obadaseraye, Oke Righteous; Fehlings, Michael G; Wilson, Jamie; Yurac, Ratko; Cook, Chad E; Milligan, Jamie; Tabrah, Julia; Widdop, Shirley; Wood, Lianne; Roberts, Elizabeth A; Rujeedawa, Tanzil; Tetreault, Lindsay; ,
STUDY DESIGN/METHODS:Delayed diagnosis of degenerative cervical myelopathy (DCM) is likely due to a combination of its subtle symptoms, incomplete neurological assessments by clinicians and a lack of public and professional awareness. Diagnostic criteria for DCM will likely facilitate earlier referral for definitive management. OBJECTIVES/OBJECTIVE:This systematic review aims to determine (i) the diagnostic accuracy of various clinical signs and (ii) the association between clinical signs and disease severity in DCM? METHODS:A search was performed to identify studies on adult patients that evaluated the diagnostic accuracy of a clinical sign used for diagnosing DCM. Studies were also included if they assessed the association between the presence of a clinical sign and disease severity. The QUADAS-2 tool was used to evaluate the risk of bias of individual studies. RESULTS:This review identified eleven studies that used a control group to evaluate the diagnostic accuracy of various signs. An additional 61 articles reported on the frequency of clinical signs in a cohort of DCM patients. The most sensitive clinical tests for diagnosing DCM were the Tromner and hyperreflexia, whereas the most specific tests were the Babinski, Tromner, clonus and inverted supinator sign. Five studies evaluated the association between the presence of various clinical signs and disease severity. There was no definite association between Hoffmann sign, Babinski sign or hyperreflexia and disease severity. CONCLUSION/CONCLUSIONS:The presence of clinical signs suggesting spinal cord compression should encourage health care professionals to pursue further investigation, such as neuroimaging to either confirm or refute a diagnosis of DCM.
PMCID:11289551
PMID: 37903098
ISSN: 2192-5682
CID: 5736462

Standards and Ethics Issues in the Determination of Death

Omelianchuk, Adam; Lewis, Ariane
PMID: 38768490
ISSN: 1539-3704
CID: 5654222

Racial disparities in the utilization of invasive neuromodulation devices for the treatment of drug-resistant focal epilepsy

Alcala-Zermeno, Juan Luis; Fureman, Brandy; Grzeskowiak, Caitlin L; Potnis, Ojas; Taveras, Maria; Logan, Margaret W; Rybacki, Delanie; Friedman, Daniel; Lowenstein, Daniel; Kuzniecky, Ruben; French, Jacqueline; ,
Racial disparities affect multiple dimensions of epilepsy care including epilepsy surgery. This study aims to further explore these disparities by determining the utilization of invasive neuromodulation devices according to race and ethnicity in a multicenter study of patients living with focal drug-resistant epilepsy (DRE). We performed a post hoc analysis of the Human Epilepsy Project 2 (HEP2) data. HEP2 is a prospective study of patients living with focal DRE involving 10 sites distributed across the United States. There were no statistical differences in the racial distribution of the study population compared to the US population using census data except for patients reporting more than one race. Of 154 patients enrolled in HEP2, 55 (36%) underwent invasive neuromodulation for DRE management at some point in the course of their epilepsy. Of those, 36 (71%) were patients who identified as White. Patients were significantly less likely to have a device if they identified solely as Black/African American than if they did not (odds ratio = .21, 95% confidence interval = .05-.96, p = .03). Invasive neuromodulation for management of DRE is underutilized in the Black/African American population, indicating a new facet of racial disparities in epilepsy care.
PMID: 38506370
ISSN: 1528-1167
CID: 5640522

Unrecognized Focal Nonmotor Seizures in Adolescents Presenting to Emergency Departments

Jandhyala, Nora; Ferrer, Monica; Pellinen, Jacob; Greenwood, Hadley T; Dlugos, Dennis J; Park, Kristen L; Thio, Liu Lin; French, Jacqueline; ,
BACKGROUND AND OBJECTIVES/OBJECTIVE:Many adolescents with undiagnosed focal epilepsy seek evaluation in emergency departments (EDs). Accurate history-taking is essential to prompt diagnosis and treatment. In this study, we investigated ED recognition of motor vs nonmotor seizures and its effect on management and treatment of focal epilepsy in adolescents. METHODS:This was a retrospective analysis of enrollment data from the Human Epilepsy Project (HEP), an international multi-institutional study that collected data from 34 sites between 2012 and 2017. Participants were 12 years or older, neurotypical, and within 4 months of treatment initiation for focal epilepsy. We used HEP enrollment medical records to review participants' initial diagnosis and management. RESULTS:= 0.03) and occurred in both pediatric and nonpediatric ED settings. DISCUSSION/CONCLUSIONS:Our study supports growing evidence that nonmotor seizures are often undiagnosed, with many individuals coming to attention only after conversion to motor seizures. We found this treatment gap is exacerbated in the adolescent population. Our study highlights a critical need for physicians to inquire about the symptoms of nonmotor seizures, even when the presenting seizure is motor. Future interventions should focus on improving nonmotor seizure recognition for this population in EDs.
PMID: 38691824
ISSN: 1526-632x
CID: 5655922

Trajectories of Inflammatory Markers and Post-COVID-19 Cognitive Symptoms: A Secondary Analysis of the CONTAIN COVID-19 Randomized Trial

Frontera, Jennifer A; Betensky, Rebecca A; Pirofski, Liise-Anne; Wisniewski, Thomas; Yoon, Hyunah; Ortigoza, Mila B
BACKGROUND AND OBJECTIVES/OBJECTIVE:Chronic systemic inflammation has been hypothesized to be a mechanistic factor leading to post-acute cognitive dysfunction after COVID-19. However, little data exist evaluating longitudinal inflammatory markers. METHODS:We conducted a secondary analysis of data collected from the CONTAIN randomized trial of convalescent plasma in patients hospitalized for COVID-19, including patients who completed an 18-month assessment of cognitive symptoms and PROMIS Global Health questionnaires. Patients with pre-COVID-19 dementia/cognitive abnormalities were excluded. Trajectories of serum cytokine panels, D-dimer, fibrinogen, C-reactive peptide (CRP), ferritin, lactate dehydrogenase (LDH), and absolute neutrophil counts (ANCs) were evaluated over 18 months using repeated measures and Friedman nonparametric tests. The relationships between the area under the curve (AUC) for each inflammatory marker and 18-month cognitive and global health outcomes were assessed. RESULTS:< 0.05), with the exception of IL-1β, which remained stable over time. There were no significant associations between the AUC for any inflammatory marker and 18-month cognitive symptoms, any neurologic symptom, or PROMIS Global Physical or Mental health T-scores. Receipt of convalescent plasma was not associated with any outcome measure. DISCUSSION/CONCLUSIONS:At 18 months posthospitalization for COVID-19, cognitive abnormalities were reported in 27% of patients, and below average PROMIS Global Mental and Physical Health scores occurred in 24% and 51%, respectively. However, there were no associations with measured inflammatory markers, which decreased over time.
PMCID:11087048
PMID: 38626359
ISSN: 2332-7812
CID: 5655822

Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

Kilburn, Lindsay B; Khuong-Quang, Dong-Anh; Hansford, Jordan R; Landi, Daniel; van der Lugt, Jasper; Leary, Sarah E S; Driever, Pablo Hernáiz; Bailey, Simon; Perreault, Sébastien; McCowage, Geoffrey; Waanders, Angela J; Ziegler, David S; Witt, Olaf; Baxter, Patricia A; Kang, Hyoung Jin; Hassall, Timothy E; Han, Jung Woo; Hargrave, Darren; Franson, Andrea T; Yalon Oren, Michal; Toledano, Helen; Larouche, Valérie; Kline, Cassie; Abdelbaki, Mohamed S; Jabado, Nada; Gottardo, Nicholas G; Gerber, Nicolas U; Whipple, Nicholas S; Segal, Devorah; Chi, Susan N; Oren, Liat; Tan, Enrica E K; Mueller, Sabine; Cornelio, Izzy; McLeod, Lisa; Zhao, Xin; Walter, Ashley; Da Costa, Daniel; Manley, Peter; Blackman, Samuel C; Packer, Roger J; Nysom, Karsten
PMID: 38467878
ISSN: 1546-170x
CID: 5694582

ABO blood type and thromboembolic complications after intracerebral hemorrhage: An exploratory analysis

Ironside, Natasha; Melmed, Kara; Chen, Ching-Jen; Dabhi, Nisha; Omran, Setareh; Park, Soojin; Agarwal, Sachin; Connolly, E Sander; Claassen, Jan; Hod, Eldad A; Roh, David
BACKGROUND AND PURPOSE/OBJECTIVE:Non-O blood types are known to be associated with thromboembolic complications (TECs) in population-based studies. TECs are known drivers of morbidity and mortality in intracerebral hemorrhage (ICH) patients, yet the relationships of blood type on TECs in this patient population are unknown. We sought to explore the relationships between ABO blood type and TECs in ICH patients. METHODS:Consecutive adult ICH patients enrolled into a prospective observational cohort study with available ABO blood type data were analyzed. Patients with cancer history, prior thromboembolism, and baseline laboratory evidence of coagulopathy were excluded. The primary exposure variable was blood type (non-O versus O). The primary outcome was composite TEC, defined as pulmonary embolism, deep venous thrombosis, ischemic stroke or myocardial infarction, during the hospital stay. Relationships between blood type, TECs and clinical outcomes were separately assessed using logistic regression models after adjusting for sex, ethnicity and ICH score. RESULTS:Of 301 ICH patients included for analysis, 44% were non-O blood type. Non-O blood type was associated with higher admission GCS and lower ICH score on baseline comparisons. We identified TECs in 11.6% of our overall patient cohort. . Although TECs were identified in 9.9% of non-O blood type patients compared to 13.0% in O blood type patients, we did not identify a significant relationship of non-O blood type with TECs (adjusted OR=0.776, 95%CI: 0.348-1.733, p=0.537). The prevalence of specific TECs were also comparable in unadjusted and adjusted analyses between the two cohorts. In additional analyses, we identified that TECs were associated with poor 90-day mRS (adjusted OR=3.452, 95% CI: 1.001-11.903, p=0.050). We did not identify relationships between ABO blood type and poor 90-day mRS (adjusted OR=0.994, 95% CI:0.465-2.128, p=0.988). CONCLUSIONS:We identified that TECs were associated with worse ICH outcomes. However, we did not identify relationships in ABO blood type and TECs. Further work is required to assess best diagnostic and prophylactic and treatment strategies for TECs to improve ICH outcomes.
PMID: 38479493
ISSN: 1532-8511
CID: 5655642